Forecast

Buy	3
Hold	2
Sell	0

News Go to news feed

Windtree Therapeutics plans acquisition of CommLoan and provides bridge financing

Windtree Therapeutics has signed a letter of intent to acquire commercial real estate fintech CommLoan; CommLoan is to continue operating as a subsidiary and key employees will remain with the company. Windtree is providing bridge financing for the transition period and sees the acquisition as a step toward diversification into revenue-generating areas. Financial details of the transaction were not disclosed; the company is currently facing a negative EBITDA of $15.34 million and a current ratio of 0.33, while the stock is trading near its 52-week low. » More on de.investing.com
Windtree Therapeutics issues $857,143 senior convertible notes in CommLoan deal

Windtree Therapeutics announced the issuance of senior convertible notes due 2026 totaling $857,142.86 to an institutional investor. Of the proceeds, $450,000 will be advanced to CommLoan and $150,000 used for general corporate purposes. The notes bear interest at 10% p.a., are convertible into common stock and include prepayment and ownership-limitation provisions; they must be repaid early upon a qualified equity financing of $1 million or more. The issuance comes against the backdrop of weak financial metrics at Windtree, prior borrowings and the resignation of the chief medical officer. » More on de.investing.com
Windtree Therapeutics issues $1.6 million convertible promissory notes due 2026

Windtree Therapeutics issued senior convertible promissory notes totaling $1.6 million, due October 9, 2026, carrying a 10% annual interest rate with monthly interest payments starting November 5, 2025. The notes are subordinated to an earlier promissory note, include conversion rights at 90% of the lowest sale price over the preceding 20 trading days, and impose beneficial ownership caps (4.99% and temporarily 9.99%). If a qualified equity financing of at least $1 million occurs, the notes must be repaid in full within one day, including accrued interest and a 120% prepayment premium. The company also reports a Nasdaq delisting, plans to file registration documents (Form S-1) within 20 days, and management and asset changes (resignation of the CMO and a $750,000 payment from a land settlement). » More on de.investing.com

Financials

In the last quarter, Windtree Therapeutics had revenue of €0 and net profit of -€23.93M

(EUR)	Sep 2025	YoY
Revenue	0	-
Gross profit	-306.77K	-
Net profit	-23.93M	-
EBITDA	-26.27M	-

Fundamentals

Metric	Value
Market capitalization	€5.82K
Number of shares	33.71M
52-week high/low	€0.16 - €0.0000863
Dividends	No
Beta	1.62
P/E ratio	0.00
PEG ratio	0.00
P/B ratio	0.00
P/S ratio	0.00

Company profile

Windtree Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entwicklung von Therapeutika zur Behandlung akuter kardiovaskulärer und in zweiter Linie akuter pulmonaler Erkrankungen konzentriert. Zu den führenden Entwicklungsprogrammen des Unternehmens gehört Istaroxim, das sich in einer klinischen Phase-IIb-Studie zur Behandlung der akuten dekompensierten Herzinsuffizienz sowie in einer klinischen Phase-IIa-Studie zur Behandlung des frühen kardiogenen Schocks befindet; AEROSURF, ein aerosolisiertes KL4-Surfactant, das sich in einer klinischen Phase-IIb-Studie zur Behandlung des Atemnotsyndroms bei Frühgeborenen befindet; lyophilisiertes KL4-Surfactant, das sich in einer klinischen Phase-IIa-Studie zur Behandlung von Lungenschäden infolge von COVID-19 befindet; und Rostafuroxin, das sich in einer klinischen Phase-IIb-Studie zur Behandlung von genetisch bedingtem Bluthochdruck befindet. Es besteht eine Zusammenarbeit mit der Universita degli Studi di Milano-Bicocca zur Entdeckung und Entwicklung neuer SERCA2a-Verbindungen für die Behandlung chronischer und akuter menschlicher Herzinsuffizienz; eine strategische Allianz mit Laboratorios del Dr. Esteve, S.A. zur Entwicklung, Vermarktung und zum Vertrieb eines Portfolios potenzieller KL4-Tensidprodukte; und eine Zusammenarbeit mit dem Battelle Memorial Institute zur Entwicklung seiner ADS für die Verwendung in seinem Phase-III-Programm. Das Unternehmen war früher als Discovery Laboratories, Inc. bekannt und änderte im April 2016 seinen Namen in Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. wurde 1992 gegründet und hat seinen Hauptsitz in Warrington, Pennsylvania. Windtree Therapeutics, Inc. ist eine Tochtergesellschaft von Lee's Pharmaceutical Holdings Limited.

Name	Windtree Therapeutics
CEO	Jed A. Latkin
Headquarters	Warrington, pa USA
Website	windtreetx.com
Sector	Consumer Staples
Industry	Food Products
IPO	08/07/1995
Employees	14